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’INTRODUCTION
Cytochrome P450 enzymes (CYPs) are prominent family of
biotransformation enzymes involved in the metabolism of xeno-
bioticsaswellasinpathwaysinvolvingvarious endogenouscom-
pounds.
1 Metabolism of drugs by microsomal CYPs plays an
importantroleinthepharmacologicalandtoxicologicaleﬀectsof
drugs as well as in related drug drug interactions in humans.
2,3
Consequently, the mechanisms whereby CYPs accommodate
varioussubstratesandoxidizetheminastereo-andregio-speciﬁc
manner are a topic of great interest in the biochemistry of the
CYPs. Current insights into determinants of substrate speciﬁcity
emerging from the available X-ray structures and biochemical
data suggest that the mechanism of substrate speciﬁcity is
complex; involving not only core active site residues but also
other structural features, for example, access/egress paths and
conformational ﬂexibility.
4 10
Human microsomal CYPs are anchored in the membrane of
the endoplasmic reticulum by their N-terminal sequence.
11,12
However, the structural data available for the CYPs are based on
analyses of engineered CYPs without the N-terminal mem-
brane anchor and often with introduced mutations designed to
enhance the protein’s solubility.
7 As a result, the current X-ray
data do not necessarily provide a comprehensive description of
the complex structures of the membrane anchored CYPs.
8,9
Despite the growth in the body of data concerning the struc-
tural features of CYPs during the past decade, the orientation
and position of CYP in the membrane at the atomic level
remains unknown. Information about the membrane topology
of CYPs is derived from indirect experiments, that is, from
epitope search,
12,13 mutagenesis,
14 16 spectroscopy,
17,18 other
experimental techniques
18 20 or from models
12,21,22 and cal-
culations based on factors such as the hydrophobicity of amino
acid residues.
7,23 These data suggests that other parts of CYP
structure, besides the N-terminal membrane anchor, are im-
mersed in the membrane; for example, part of N-terminal
domain and the F/G loop.
12,24,25
One aspect of CYP function involves the oxidation of hydro-
phobicsubstratestomakethemmorehydrophilic(forschematics
of the enzyme action see Figure 1). In this respect, a question
arises as to how the lipophilic substrates enter the buried active
sites of CYPs? From mutation studies, it has been suggested that
substrate access channels of CYP enzymes might be located in
partsoftheproteineitherinclosecontactorinsidethemembrane
andthatthelipophilicsubstratesmayentertheactivesitefromthe
membrane via an appropriate access channel.
26 Access channels
fromfamily2(orpw2,accordingtoWade’snomenclature
5)seem
to be suitable for passage of substrates to the active site. Similarly
another important question is how and where the more hydro-
philic products are released from the active site. The solvent
channel of CYPs has been identiﬁed as a passage enabling active
site solvation;
8,27 such a hydrophilic channel may also serve as a
potentialegresschannelforthemetabolites.
26However,theexact
positionsoftheopeningsoftheaccess/egress channelsinrespect
to the membrane remain to be determined.
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ABSTRACT: Cytochrome P450 2C9 (CYP2C9) is a membrane-anchored human micro-
somal protein involved in the drug metabolism in liver. CYP2C9 consists of an N-terminal
transmembrane anchor and a catalytic cytoplasmic domain. While the structure of the
catalytic domain is well-known from X-ray experiments, the complete structure and its
incorporation into the membrane remains unsolved. We constructed an atomistic model of
complete CYP2C9 in a dioleoylphosphatidylcholine membrane and evolved it by molecular
dynamics simulations in explicit water on a 100+ ns time-scale. The model agrees well with
known experimentaldataaboutmembranepositioningofcytochromesP450.Theentrytothesubstrateaccesschannel isproposed
to be facing the membrane interior while the exit of the product egress channel is situated above the interface pointing toward the
water phase. The positions of openings of the substrate access and product egress channels correspond to free energy minima of
CYP2C9 substrate ibuprofen and its metabolite in the membrane, respectively.11249 dx.doi.org/10.1021/jp204488j |J. Phys. Chem. A 2011, 115, 11248–11255
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Here we present an atomic model of the membrane-anchored
enzyme CYP2C9, the major CYP2C form in human liver, which
is responsible for the biotransformation of both weakly acidic
drugs such as ibuprofen and many endogenous compounds.
1,2,28
Themodeliscross-validatedwiththeavailableexperimentaldata
andprovidesimportantinformationaboutmembraneanchoring,
thestructuralchangesCYP2C9undergoesuponinteractingwith
the membrane and the orientations of the access/egress path
within this structure. The calculated free energy proﬁles of
ibuprofen and its metabolite (3-hydroxyibuprofen) show the
disposal (penetration depth) of these compounds in the mem-
brane. The mechanisms of substrate access and product release
are further discussed with respect to the proposed positions of
the substrate and product entrance in/on the membrane.
’MATERIALS AND METHODS
Protein Model Building. We used the crystal structure of
ligand-free CYP2C9 (PDB ID 1OG2) as a template for model
building.
29 Thesequence oftheengineeredCYP2C9wasaligned
withthesequenceofwild-typehumanCYP2C9todetectinserted
mutationsandwithsequencesofrabbitCYP2B4andratCYP2B1
tocompare the experimentaldata onmembranetopology.Multi-
ple alignment was performed using ClustalW2
30 within Jalview
2.6
31 (see Figure S1).
Membrane positioning data were collected mainly from
epitope screening of rat CYP2B1 and rabbit CYP2B4,
12,13,32
and from knowledge of phosphorylation
12 and mutations in the
CYP2Cfamily.
15,25Datafromepitopescreeningrevealedregions
that are inaccessible to the antibodies (i.e., buried inside the
protein or within the membrane).
Model building was done in Pymol 0.99rc6.
33 To begin with,
the rescue mutations (E206K, V215I, Y216C, P220S, A221P,
L222I, L223I) were applied to restore the wild-type sequence of
CYP2C9. The transmembrane segment was modeled as R-helix
andjoinedtotherestoftheproteinbyaﬂexiblearm.Theprotein
was then immersed into a membrane modeled on known
membrane segments derived from multiple alignment (see
FigureS1inSupportingInformation).Thetransmembrane helix
was rotated within the membrane to be approximately perpen-
dicular to the membrane surface.
More than 50% of the membrane of the endoplasmic reticu-
lumconsistsofphosphatidylcholines.
34Duetothisfact,webased
our model membrane on an equilibrated dioleyolpalmitoyl-
phosphatidylcholine(DOPC)membranewithatopologydown-
loaded from http://www.bioinf.uni-sb.de/RB.
35 The membrane
was oriented perpendicular to the z-axis of the box.
Protein/Membrane Simulation Protocol. Molecular dy-
namics simulations were used to study the stability of the model
withtheunited-atomGROMOS9653a6forcefield
36withBerger
lipid addition
37 in Gromacs 4.0.7.
38 Parameters of heme were
takenfromthe53a6forcefield.SPCwatermoleculesandchloride
and sodium ions were added to neutralize the system and to
achieve a cellular salt concentration of 0.1 mM. After energy
minimization, 200 ps long prerun was performed to equilibrate
water molecules with simultaneous position constraints on pro-
tein heavy atoms. The system was then equilibrated in the NPT
ensemble for a further 10 ns to equilibrate pressure and box size
with an anisotropic Berendsen barostat with a time constant of
10 ps and pressure of 1 bar and V-rescale thermostat with a time
constant of 0.1 ps and with temperature of 300 K. Three
independent production simulations in the NPT ensemble were
then run for a total time of 250 ns. The system equilibrated after
30 ns (for comparison between initial and final model see Figure
S2 and for evolution of rmsd see Figure S3 in Supporting
Information).
Access Channels Analysis. The access/egress channels were
calculated using MOLE (http://mole.chemi.muni.cz) software.
39
MOLE outperforms the previously released CAVER,
40 which is
widely used for studies of biomolecular channels and has been
successfully applied to the study of CYPs.
5,8,41
Drug Disposition Simulations. To establish the disposition
of drugs in the membrane/water environment, the respective
drugmoleculesweresubjectedtosimulationinthesameDOPC/
water environment. Gromos96 parameters for the model drug
(in this case ibuprofen, a typical substrate of CYP2C9) and its
metabolite (3-hydroxyibuprofen) were obtained from the Dun-
dee PRODRG 2.5 Beta server.
42 Ibuprofen (and also 3-hydro-
xyibuprofen) was modeled in both its uncharged and charged
protonation states. Free energy profiles were calculated with the
g_wham program.
43 Profiles were calculated by umbrella sam-
pling of the potential of mean force on 45 windows with spacing
of 1 Å defined on the membrane normal using a harmonic
potential with a force constant of 1000 kJ3mol
 1
3nm
 2. Each
window was run twice for at least 3 ns: the windows with
substantial gradients were run for a longer period with twice as
highforceconstanttominimizeerror.Startingstructuresforeach
window were obtained from free simulations with the molecule
starting in water or from pull simulations with force applied on
the drug in the direction normal to the membrane.
’RESULTS
Model Building. The N-terminal sequence missing from
the initial X-ray structure PDB ID 1OG2
29 was modeled as an
R-helix. The R-helix topology is typical for a single transmem-
brane segment as it is able to accommodate the hydrogen bond-
ing of the main-chain atoms in a nonpolar environment. The
R-helical topology was consistent with the findings of an NMR
study of the N-terminal transmembrane segment from prosta-
glandin I2 synthase (also known as CYP8A1).
44 The trans-
membrane R-helix was terminated by a positively charged N-
terminus.
1 The R-helix was attached to the CYP2C9 structure
Figure 1. In this work we discuss several structural aspects of CYP2C9
anchoredtothemembraneatatomicresolution.Theschemeshowsthat
it is hypothesized that hydrophobic substrates (S) enter the CYP
enzyme active site (AS) via an access channel (ACh). The substrate is
oxidized in the active site to a more hydrophilic product (P) and leaves
the active site via an egress channel (ECh) to cytosol. The oxidation
involves heme (HEME) and requires electrons, which can be provided
by cytochrome P450 reductase (CPR).11250 dx.doi.org/10.1021/jp204488j |J. Phys. Chem. A 2011, 115, 11248–11255
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and the mutations introduced into the 1OG2 structure were
modifiedtothenativewild-typesequenceofCYP2C9.Theinitial
orientationoftheCYP2C9 structure onthemembraneaswellas
the depth of the part embedded in the membrane were based on
known experimental data from epitope labeling, which indicate
parts of CYP inaccessible to the antibodies, that is, those inside
the protein or within the membrane.
12,13,32 Arbitrary orienta-
tions of the CYP2C9 with respect to the membrane were chosen
formoleculardynamics(MD)simulationsandallofthesesystems
relaxed to the topology resembling the orientation of the final
model (data not shown). A snapshot taken from the equilibrated
part of our simulation was used as a final model (Figure 2).
The model presented here provides some new insights and
answers, but it should be noted that the model is based on
classicalMD simulations, whichare limited mainly by thequality
of the empirical force ﬁeld and available time scales. The 100 ns
longtimescaleofMDsimulationenableslimitedsamplingofthe
conformational space, that is, the molecules typically ﬂuctuate
close to their starting structures (this limitation is also known as
the “local conformational trap”). Enhanced sampling can be in
principle achieved, for example, by coarse-grained MD simula-
tions using even more simpliﬁed coarse-grained potentials. The
coarse-grained simulations, however, may suﬀer from the charge
artifacts and also conformational changes of the protein back-
bone are not adequately described.
45 Both atomic and coarse-
grained MD simulations should be always cross-validated with
available experimental data and interpreted with care keeping in
mind their inherent limitations.
Final Model Cross-Validation. The most important part of
the model building is its cross-validation against available experi-
mental data. In our analysis all of the simulations were stable and
the protein was relatively rigid. The membrane topology did not
change significantly from that used as an input. From this
perspective it is not surprising that the information gathered
from the epitope screening,
12,13,32 which was used as the main
input information during the model construction (see Methods
section for details), were also valid for the final model. The
regions inaccessible to the antibodies are inside the protein
(positions 93 98, B0-helix, and 287 299, I-helix) or within
the membrane (positions 1 46, N-terminal anchor, and 207 
220, F/G loop).
Protein rotation studies on several CYPs shows that the tilt
angle between the heme plane and the membrane plane is
variable for diﬀerent CYPs from approximately 38 to 78.
46
The tilt angle between the heme and the plane of the membrane
was(35(5)inoursimulations;however,thisisstillacceptably
consistent with the experimental data.
A tryptophan ﬂuorescence scanning study on CYP2C2 sug-
gested that tryptophan residues within the A-helix and the β2-2
sheet (positions 36, 69, and 380) are positioned within the
membrane as their ﬂuorescence was quenched by the probes
with nitroxide spin labels on fatty acid tails.
47 The authors
concluded that the F/G-loop (position 225) is not localized
within the membrane. However, the immersion of the F/G-loop
in the membrane is based on observations from previous ﬂuo-
rescent studies,
48 mutagenesis,
15,25,29 and trypsinolysis.
49,50 This
apparent paradox could possibly be resolved by considering the
homodimerization of CYPs from the 2C family. The dimeriza-
tioninterfaceincrystalstructuresoftruncatedCYP2C8(whichis
highly homologous to CYP2C9) is formed by the F/G-loop
region even with lipids bound.
51 The F/G loop was also
identiﬁed recently to be at the dimerization interface even in
physiological membranes in addition to the N-terminal signaling
domain.
52,53Dimersaremainlyformedathigherconcentrations;
atlowerconcentrations,CYP2C8existsprimarilyasthemonomer.
51
Because the concentrations of CYPs in the tryptophan ﬂuores-
cence scanning study were quite high due to their increased
expression in the insect cells,
47 it is possible that the majority of
CYPs were dimers under these conditions and that these dimers
were likely in contact by the F/G-loop region. The F/G-loop
region also forms the dimeric surface with lipids present in the
CYP2C8 crystal structure PDB ID 2NNH.
51 On the other hand,
older data from trypsinolysis and epitope searching were mainly
collectedfromstudieson microsomeswithlower concentrations
of CYPs, where the CYPs may be present mainly in the form of
monomers. Our model represents a monomeric CYP2C9 with
an F/G loop and A0-helix inside the membrane. On the other
hand,wecannotruleoutapossibilitythatthemembraneposition
of F/G-loop depends on local conditions (e.g., formation of
oligomers) or dynamics equilibrium beyond our simulation
time scale.
The position of CYPs in the membrane has also been studied
by AFM
19,54 and the Langmuir Blodgett monolayer technique.
20
It was found that the height of the CYP above the membrane is
approximately 3.5 ( 0.9 nm and that it occupies an area of 6.8 (
0.95 nm
2 in the membrane. Therefore, not only the transmem-
brane helix of the CYP but also a part of the catalytic domain is
partially immersed in the membrane. The maximal height of
CYP2C9 above the membrane was ∼4 nm in our model and the
area of the protein in the membrane was slightly more extensive
than 8 nm
2. However, some of the lipid molecules were inter-
calated between the A0-helix and the F/G loop and they
contributed to the enlargement of this area. Taken together, this
information suggests that our model ﬁts reasonablywell with the
available experimental data and is valid for further analyses.
Final Model Description. The protein was stable and rela-
tively rigid in all simulations (see the plot of rmsd in Figure S3).
The most flexible parts, according to the calculated root-mean-
square fluctuations (RMSF, which can be transformed to B-fac-
tors as Bf = 8/3π
2 RMSF
2), were mostly those of the N-terminal
transmembrane helix or the loops which were exposed to water.
Interestingly, the F/G loop, flexible in some CYPs,
6 was more
rigid in CYP2C9 on the membrane. The central part of the
Figure 2. Snapshot of the structure of CYP2C9 in DOPC membrane
taken at50 ns.Theproteinisshowningreen,whileparts determinedby
epitope screening as not being exposed to water (i.e., in the membrane
or inside the protein core) are shown in violet. Parts predicted to be
accessible to water are shown in blue. Heme is shown by red spheres.
The DOPC membrane is shown using the transparent stick representa-
tion with orange spheres at the positions of phosphorus atoms in the
lipid beads. The image was prepared with Pymol 0.99rc6.
33.11251 dx.doi.org/10.1021/jp204488j |J. Phys. Chem. A 2011, 115, 11248–11255
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protein close to the catalytic site was also rigid (see Figure 3).
The flexible N-terminal anchor retained R-helical topology, with
a bend at the Arg21 position (see Figure S4 in Supporting
Information).
The membrane was rather ﬂexible and it adapted to the
presence of the hydrophobic tip of protein composed from the
N-terminal transmembrane domain, the A0-helix and the F/G-
loop.InthevicinityoftheN-terminalanchor,thethicknessofthe
membrane decreased from the initial value of ∼40 Å (the mean
distance between two phosphoric groups on the opposite sides
of the free DOPC membrane) to ∼33 Å. The adaptation to the
protein also resulted in a thickening of the membrane to ∼46 Å
inthecontactregionclosetotheF/GandK/Lloops.After10ns
of equilibration in the simulation, there were no other signiﬁcant
changes in the membrane topology.
To function, CYPs require CYP reductase (CPR) as a source
of electrons (cf. Figure 1). CYP and CPR are both membrane-
bound proteins
55 and the membrane facilitates contact between
theproteins.Theﬁnalmodelshouldtherefore enableCYP/CPR
complex formation. The positions of interacting residues were
detected experimentally by mutational study on the aﬃnity of
CYP2B4towardCPR.
56ThecorrespondingresiduesinCYP2C9
are K121, R125, R132, F134, M136, K138, K432, and G442 (see
FigureS1).AlloftheseresiduesonthesurfaceoftheCYP2C9are
accessible to water and available for interaction with CPR in our
model (Figure 4).
Effects of the Membrane on the CYP Structure and
Flexibility. The RMSF profile calculated from the simulation
ofCYP2C9basedon1OG2X-raystructureagreeswellwithpub-
lished results and displays the previously identified common
flexible regions.
6,8 The simulation of CYP2C9 with the attached
N-terminal anchor displays a similar RMSF pattern besides the
extremelyflexibleN-terminalanchor.ThesimulationofCYP2C9
in the membrane also shows the same RMSF pattern as simula-
tions of CYP2C9 in water. However, the flexibility of the part
of the enzyme in contact with the membrane (specifically the
N-terminal part and the C/D and F/G loops) is somewhat
decreased.ThediffusionofCYP2C9isalsoslowedbythepresence
of the membrane (see Table S1 in Supporting Information).
’DISCUSSION
Comparison to Empirical Membrane Topology Models
from the Literature.Previous studies have attempted to predict
CYP membrane topology on the basis of the surface hydro-
phobicity and available experimental data; our model of wt
CYP2C9 is the first atomistic model of the membrane topology.
Figure 5 shows a comparison of these predictions and their
variabilities. Themostsimilarpositioningtoouratomisticmodel
providedbythePPM 2.0computational approach
23isapplied to
the complete wt CYP2C9 structure with the N-terminal anchor
(cf. white and orange membrane planes in Figure 5). The main
difference is in the change in the membrane thickness in the
vicinityoftheCYP,whichisnotaccountedforinPPMcalculations.
Figure 3. Left panel shows B-factors mapped onto the structure calculated from individual 100 ns long simulations of CYP2C9 in membrane. The
B-factors are colored by spectrum from dark blue for rigid regions to red for the most ﬂexible regions. Heme is shown in magenta and membrane lipids
are shown in gray with orange spheres for phosphoric atoms. Right panel shows RMSF per residue for simulations of wt CYP2C9 in membrane (black
line), wt CYP2C9 in water (green line), CYP2C9 based on crystal structure 1OG2 (without N-terminal anchor) in water (red line), as well as RMSF
calculated from the B-factors of crystals structures 1OG2 and 1OG5 (cyan and blue lines, respectively). The ﬁgure shows that the most ﬂexible parts of
themoleculearetheN-terminalanchor(FR1),G/Hloop(FR5),K/Lloop(FR9),andC-terminus(FR10).Interestingly,theF/Gloop,whichisﬂexible
in some CYPs, isratherrigid.
6 Also,the centralpart ofthe proteinclose to the catalytic site isrelatively rigid. Thesimulation ofCYP2C9 in watershows
highly enhanced ﬂexibility of the N-terminal part (FR1) and of the F/G-loop (FR6) in comparison with simulation of CYP2C9 anchored to the
membrane. The proﬁles of RMSF calculated from all simulations have similar trends, which also agree well with published data.
6 8.
Figure 4. Proximal side of CYP2C9 anchored to DOPC membrane is
accessible to water and CYP reductase (CPR). These two views of
CYP2C9 show amino acids responsible for binding to CPR (K121,
R125, R132, F134, M136, K138, K432, and G442 shown in orange and
heme shown in red). These amino acids are present on the CYP
proximal side surface.
56 CPR-binding amino acids are accessible to
water in our model.11252 dx.doi.org/10.1021/jp204488j |J. Phys. Chem. A 2011, 115, 11248–11255
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If the transmembrane segment is not present (1OG2), the predic-
tion incorrectly exposes residues around the N-terminus to the
solvent (Figure 5, blue). The other topologies adopted from the
literature indicate that the N-terminus should be inside the
membrane, but they show either too shallow immersion of CYP,
asshowninFigure5,incyan,
57inyellow,
58ordeeperimmersion.
59
Effects on Access and Egress Channels of CYP2C9. An
intriguing question of CYP biochemistry is how substrates enter
and products leave the active site, which is buried deep inside
the CYP structure. The active site is connected to the outside
environment by a network of access/egress channels, which may
enable passage of a substrate to, and a product from, the active
site.
5,57,60 62 However, there are at least two important and
unanswered questions. Does the CYP molecule undergo a large
conformational change during substrate binding and product
release and which channels enable access and which enable
egress?
Our MD simulations do not show any large conformational
changes in the CYP2C9 anchored to the membrane. CYP2C9
retainsitstopologyandRMSFindicatesdecreasedﬂuctuationsof
CYP2C9 in the membrane in respect to CYP2C9 in water. This
implies that common structural features and variations of CYP,
derivedfromX-raystructuresofengineered CYPs,
7arealsovalid
for wild-type CYPs. However, some larger structural changes
(namely, in the active site upon binding of larger substrates
63)o f
membrane-anchored CYP cannot be ruled out because of the
above-mentioned limitation of our MD simulations.
The access/egress channels were analyzed by MOLE software.
39
We adopted the nomenclature of access/egress channels intro-
duced by Wade and co-workers.
5 The X-ray structure of 1OG2
indicatesthepossibleactivesiteaccesspaths,thesolventchannel
and the 2c channel (between the B0 and G helices). During the
MD simulations of CYP2C9 in water the solvent channel closes
andthe2cchannelopenswider.Theanalysisoftheﬁnalmodelof
CYP2C9 in the membrane identiﬁed the solvent channel as the
widest active site access channel (for further analysis, see Figure
S5 in Supporting Information). Solvent channel points slightly
above the interface between the membrane and water. Channels
from the 2x family (which are mostly closed having bottleneck
radii below 1.5 Å) are pointing into the membrane; whereas 2b
and 2c channel openings are facing the interface (see Figure 6).
Effects on Drug Disposition and Metabolism. To shed
some light to the question how substrates enter and products
leave the CYP buried active site, we investigated the position
(penetration depth) of a typical CYP2C9 substrate, ibuprofen
and its metabolite (3-hydroxyibuprofen), in the membrane. The
positions were identified as minima on the free energy profiles
along the z-axis, which was perpendicular to the membrane (see
Figure 7). Potential of mean force simulations on the DOPC
membrane/water boundary showed that the free energy profiles
of both molecules have different positions of minima (see
Table1).Whilenegativelychargedibuprofenpreferstobeinside
the membrane perpendicular to the membrane plane with its
carboxyl group attached to the positively charged choline group
in the DOPC bead, the neutral ibuprofen prefers the hydro-
phobic membrane interior (see Figure 7). The position of ibupro-
fen agrees with previous work by Boggara and Krishnamoorti.
64 In
contrast, the hydroxylated metabolite is only weakly bound to the
Figure 5. Comparison of models of embedding the CYP2C9 protein
into the membrane. Planes of membrane upper layer (approximately at
the glycerol level) are colored as follows: This work (orange), Williams
et al.
25 (yellow), Wade et al.
57 (cyan), Zhao et al.
59 (red), Lomize et al.
PPM2.0proteinmembranepositioningapproachfor1OG5fromOPM
database http://opm.phar.umich.edu/
23 (blue), and the same PPM 2.0
approach applied to on our wt CYP2C9 model with the N-terminal
anchor present (white). As the OPM database shows the planes of
positions for the hydrophobic slab, PPM planes were shifted by 10 Å
upward to be consistent with other planes at the glycerol level.
Figure 6. Positions of access/egress channels within membrane an-
chored CYP2C9. Left panel shows the model of CYP2C9 in DOPC
membrane. Protein isshown in dark gray cartoon representation. Heme
is shown by red balls. DOPC membrane is shown in wires. The most
widely open active site access channel is solvent channel (blue). The
mouth opening of the solvent channel is slightly above the membrane-
water interface. Channels from 2x family are shown in an order following
their opening during the simulation (see Figure S5 in Supporting Infor-
mation) as follows: 2c (green), 2ac (cyan), 2b (yellow), 2e (magenta), 2f
(orange), and 2a (red). All of the openings of these channels are pointing
intothemembrane;however,the2band2cchannelopeningsarepointing
into the headgroup region interface. Access channels were analyzed by
MOLE
39withPymol0.99rc6.
33Rightpanelshowsschematicaldescription
of the positions of above-mentioned channels of our model.11253 dx.doi.org/10.1021/jp204488j |J. Phys. Chem. A 2011, 115, 11248–11255
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membrane surface and its incorporation into the membrane is
energetically highly disadvantageous (see Figure 7). The incor-
poration of small and rigid molecules (such as cholesterol) is
connected with changes in the membrane flexibility and phase
transitions.
65 In this respect, it can be hypothesized that CYPs
may “sweep out” the membrane by increasing the solubility of
low-polar xenobiotics in water, for example, ibuprofen.
It should be noted that there is a signiﬁcant energy penalty for
charged forms for crossing the membrane, whereas uncharged
forms prefer the central part of the membrane. The penalty is
c o n n e c t e dw i t ht h ei n t r o d u c t i o no faw a t e r - ﬁlled hole in the
membrane structure, which is ﬁlled by the water molecules
attachedtothechargedcarboxylicgroupofibuprofen.Therefore,
a possible model of transfer of ionizable drug across the mem-
brane consists of these steps: (i) the drug is attached into the
membrane interior with part of the molecule, (ii) the drug
is neutralized, (iii) the drug is transferred across the membrane
center, and (iv) the drug is recharged on the other side of
membrane. The height of the energy barrier across the mem-
brane and depth of free energy minima deﬁne the drug penetra-
tion across the membranes and drug partitioning between water
and membrane.
66 Both of these properties contribute to deter-
mining the drug disposition in the organism.
The minimum of free energy for ibuprofen is located at the
positionbellowthephosphategroups.Thispositioncorresponds
approximately to the entrance to the 2x channels. On the other
hand, the minimum for 3-hydroxyibuprofen is located approxi-
mately at the position of the solvent channel mouth opening
(Figure 7). Hence, we can further hypothesize that the 2x
channels are involved in the substrate access into the CYP active
site and the solvent channel is used for the metabolite egress.
This also coincides with information from studies that show that
the solvent channel is lined by polar residues enabling active site
solvation
8,27 and the 2x channels are in this respect considerably
less polar. On the other hand, we cannot rule out the possibility
that other (e.g., more polar) substrates can enter the active site
via solvent channel and also that some substrates can share the
same path for substrate access and product egress.
Figure 7. Positions of CYP2C9 substrate ibuprofen and its metabolite on membrane. The upper left part shows partial densities of selected groups on
the DOPC membrane/water boundary, while the lower part shows free energy proﬁles for ibuprofen and 3-hydroxyibuprofen. Free energies were
calculated by the potential of meanforce imposed on the distance in the z-axis between the center-of-mass ofthe drug and membrane. Zero freeenergy
was arbitrarily selected in the distance of 3.5 nm from the center of the membrane (i.e., in water). The free energy proﬁle for uncharged ibuprofen was
shiftedbythefreeenergycalculatedfromtheibuprofenacidityconstantinwaterandforpH7by3.5kcal/mol(14.6kJ/mol).Theschemeofprotonated
ibuprofen highlighted with an arrow shows the oxygenation site at position 3 and approximate positions of the opening for 2x and solvent channels are
shown by magenta and blues arrows, respectively. The structures on the right side were selected from the window taken from umbrella sampling with
minimal free energy. Notethat while neutral ibuprofen is in the center ofthe membrane without any contact with the water environment, both charged
molecules are in contact with water molecules mediated by their charged carboxylic group (shown in red). The more polar 3-hydroxyibuprofen is
however more exposed to water by its hydroxyl group as shown by black arrow. The ﬁgure was prepared in Pymol 0.99rc6.
33.
Table 1. Free Energy Minima for Molecules in DOPC
Membrane
a
minimum of free energy
molecule
distance from
center of membrane [nm]
ΔG
[kcal/mol]
(kJ/mol)
ibuprofen
(neutral, charge 0)
0.1  9.6 ( 0.7 ( 40.2 ( 2.9)
ibuprofen
(charge  1)
b
1.4  11.0 ( 0.1 ( 46.0 ( 0.4)
3-hydroxyibuprofen
(neutral, charge 0)
1.4  2.4 ( 0.8 ( 10.0 ( 3.3)
3-hydroxyibuprofen
(charge  1)
b
2.2  2.7 ( 0.1 ( 11.3 ( 0.4)
aData were calculated by the potential of mean force simulations on
DOPC/water membrane. The distance of the carboxylic group to the
center-of-mass of the ibuprofen is approximately 5 Å. See Figure 7 for
structures corresponding to respective minima.
bPreferential form in
wateratpH=7(ibuprofenpKa=4.44,the samevaluewas alsousedasa
guess for 3-hydroxyibuprofen).
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’CONCLUSIONS
We have constructed an atomic model of CYP2C9 in DOPC
membrane; its features were cross-validated with available ex-
perimentaldatafromepitopescreening,atomicforcemicroscopy
measurements, mutagenesis, and ﬂuorescence studies. This
model is also consistent with homodimerization and interaction
of CYP2C9 with the CYP reductase. The transmembrane helix,
1 1sheet,A0,G 0 helices arelocatedwithin themembrane,while
A, B0,F 0, G helices are located on the membrane surface. The
membrane anchor is mostly R-helical and is kinked in the
membrane at position R21.
The entrance (mouth opening) of the 2x channels points
toward the hydrophobic part of the membrane and position of
their openings corresponds to the free energy minimum
(∼1 nm deep in the membrane) of ibuprofen, which is a
CYP2C9 substrate. The mouth opening of solvent channel is
positioned in themembrane/solventinterface,corresponding
totheminimaoffreeenergyproﬁleoftheibuprofenoxidation
product on the membrane/water environment (see Figure 8).
Therefore,2xchannels(possiblywith exception of 2b,2c, and
2e channels) may be involved in substrate binding (at least of
low polar substrates), and the solvent channel is likely to be
involved in the product release. The proposed mechanism of
drug-binding may be shared among all membrane-bound
microsomal CYPs.
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